PerkinElmer Unveils Cell Analysis Solution

Published on: 

PerkinElmer has unveiled a cell analysis solution to streamline cell and gene therapy research and manufacturing.

PerkinElmer announced on Sept. 26, 2022 that it has launched the Cellaca PLX Image Cytometry System, a platform designed to enable researchers to assess multiple Critical Quality Attributes (CQAs) of cell samples in a single automated workflow; this includes cell identity, quality, and quantity.

The system combines image cytometer hardware, software, validated consumables, and trackable data reporting; it is designed to eliminate complex calibration procedures or intense training requirements. According to a company press release, the new offering will provide researchers expanded cell sample CQA analysis options beyond flow cytometry and staining methods, which have historically required a variety of different instruments and analytical methods. By combining these capabilities, researchers can detect multiple markers simultaneously and perform immunophenotyping and viability assays in seconds.

"Pharmaceutical companies have invested heavily in cell and gene therapy, but they struggle to assess the complex cell samples required to meet immense scientific demands and regulatory rigor across their research and manufacturing processes," said Alan Fletcher, senior vice-president, Life Sciences, PerkinElmer, in the release. "While the Cellaca PLX Image Cytometer platform is therapeutic area agnostic, it is expected to be especially beneficial for researchers working in CAR-T cell therapy who want to streamline their phenotyping of immune cells for downstream processes."


Source: PerkinElmer